Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | HPGD | P15428 | 6/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30762931 | 1.00 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4ERECQLHSD17B10 | |
| SCHEMBL20839145 | 1.00 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4ERECQLHSD17B10 | |
| SCHEMBL30231474 | 0.90 | ALDH2 (0.61) | ALDH1A1HPGDKDM4ERECQLHSD17B10 | |
| SCHEMBL30762863 | 0.88 | ALDH1A1 (0.57) | ALDH1A1HPGDKDM4ERECQLHSD17B10 | |
| SCHEMBL30762862 | 0.88 | ALDH1A1 (0.49) | ALDH1A1HPGDKDM4ERECQLHSD17B10 | |
| SCHEMBL20839326 | 0.88 | ALDH1A1 (0.49) | ALDH1A1HPGDKDM4ERECQLHSD17B10 | |
| SCHEMBL20847991 | 0.88 | ALDH1A1 (0.57) | ALDH1A1HPGDKDM4ERECQLHSD17B10 | |
| SCHEMBL20839167 | 0.88 | ALDH1A1 (0.57) | ALDH1A1HPGDKDM4ERECQLHSD17B10 | |
| SCHEMBL30360979 | 0.88 | ALDH1A1 (0.57) | ALDH1A1HPGDKDM4ERECQLHSD17B10 | |
| SCHEMBL26115868 | 0.87 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4ERECQLHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684762-B1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | disclosed |
| WO-2023034339-A1 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034340-A1 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2021-09-07 | — | — | US | disclosed |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
| WO-2019057821-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | POLRMT, UQCRC2, UQCRC1 | ALDH1A1 1261/4885HPGD 947/4885KDM4E 2362/4885 |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | POLRMT, UQCRC2, UQCRC1 | ALDH1A1 1261/4885HPGD 947/4885KDM4E 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.